CI
SMMT icon

CX Institutional’s Summit Therapeutics SMMT Stock Holding History

CX Institutional’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9K Sell
591
-257
-30% -$4.56K ﹤0.01% 1314
2026
Q1 		$16K Buy
+848
New +$13.7K ﹤0.01% 1186

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

CX Institutional's SMMT Position: Q2 2026 in Review

CX Institutional reduced its Summit Therapeutics (SMMT) stake by 30% in Q2 2026, selling an estimated $4.56K and leaving 591 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

CX Institutional first reported a position in SMMT in Q1 2026 and has held it in 2 quarters since. The position peaked at $16K in Q1 2026. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • CX Institutional held 591 shares of Summit Therapeutics worth $9K as of Q2 2026.
  • CX Institutional sold 257 Summit Therapeutics shares in Q2 2026, an estimated $4.56K.
  • Summit Therapeutics made up ﹤0.01% of CX Institutional's portfolio in Q2 2026, its #1314 holding.
  • CX Institutional first reported a position in Summit Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • CX Institutional's Summit Therapeutics position peaked at $16K in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on CX Institutional's 13F filing for Q2 2026, filed 2 Jul 2026.